WASHINGTON — AstraZeneca may have included “outdated information” in touting the effectiveness of its COVID-19 vaccine in a U.S. study, federal health officials said Tuesday in an unusually public rift that could further erode confidence in the shot. In response, AstraZeneca said that it is working on more up-to-date information. The more recent findings are consistent with its initial announcement that the vaccine offered strong protection. It promised an update within 48 hours. In an extraordinary rebuke, just hours after AstraZeneca on
Monday announced its vaccine worked well in the U.S. study, an independent panel that oversees the study scolded the company for cherry-picking data, according to a senior administration official. The board wrote to AstraZeneca and U.S. health leaders that it was concerned the company chose to use data that was outdated and potentially misleading instead of the most recent and complete findings, according to the administration official, who discussed the contents on the condition of anonymity given the sensitivity of the matter.